Bioton (BIO.WA) Azione Prezzo
Bioton Prezzo
Negli ultimi 19 anni Bioton ha aumentato il fatturato del 1,4% all'anno, raggiungendo 282,52 Mio. PLN. L'utile per azione è diminuito del 16,0% all'anno negli ultimi 19 anni. Per Bioton, il margine netto del 1,2% risulta sostanzialmente stabile rispetto al 1,8% di alcuni anni fa.
Bioton Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Bioton Azione e analisi azionaria
Domande frequenti sull'azione Bioton
The business model of Bioton SA revolves around the development, manufacturing, and distribution of innovative biopharmaceutical products. Bioton SA specializes in the production of recombinant human insulin and insulin analogs, addressing the needs of diabetic patients worldwide. The company focuses on research and development activities to continuously improve their products and expand their portfolio. Bioton SA strives to provide high-quality and affordable healthcare solutions, catering to the growing demand for diabetes treatment options. With their strong commitment to innovation and patient care, Bioton SA aims to establish itself as a leading player in the biopharmaceutical industry.
Bioton SA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Bioton SA in the market are Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, and Merck & Co., Inc.
Bioton SA is a renowned pharmaceutical company with a rich history and background. Established in 1989, Bioton SA has become a pioneer in the field of biotechnology and specializes in the development, production, and marketing of innovative pharmaceuticals. With its headquarters in Poland, Bioton SA has successfully expanded its operations globally. The company has made significant contributions to the medical industry through its cutting-edge research and development efforts, particularly in the fields of diabetes and human insulin production. Bioton SA continuously strives to provide high-quality products and improve global healthcare standards, solidifying its position as a leading player in the pharmaceutical sector.
Bioton SA, a leading pharmaceutical company, has achieved remarkable milestones throughout its existence. The company garnered global recognition for its groundbreaking advancements in the field of biotechnology. Bioton SA successfully introduced innovative pharmaceutical products, including insulin and other life-saving medications, revolutionizing the treatment of diabetes and various other medical conditions. Moreover, the company's dedicated research and development efforts have enabled Bioton SA to expand its product portfolio and consistently deliver high-quality therapeutic solutions to meet the growing healthcare needs of patients worldwide. Bioton SA's commitment to excellence and continuous innovation has established it as a prominent leader in the pharmaceutical industry.
Bioton SA is primarily present in Poland, where it is headquartered. Additionally, Bioton SA has a significant presence in the European market, specifically in countries such as Germany, France, and the United Kingdom.
Bioton SA is a leading biotechnology company that represents a strong set of values and corporate philosophy. The company values innovation, research, and development to provide cutting-edge solutions in the field of biotechnology. Bioton SA focuses on providing high-quality healthcare products and services to improve people's lives. With a commitment to excellence and a customer-centric approach, Bioton SA aims to deliver value to its stakeholders. The company's philosophy centers around sustainable growth, ethical practices, and fostering partnerships to drive success. Bioton SA's dedication to scientific advancement and ethical business conduct makes it a trusted name in the biotechnology industry.
Convertita al tasso di cambio attuale, l’azione Bioton quota 0,85 EUR (3,72 PLN).
L’azione Bioton (BIO.WA) è quotata su 4 borse, tra cui: London (0DTR.L), Frankfurt (7U5.F).
Bioton SA is a Polish biotechnology company that specializes in the development and production of biotechnological and medical products. The company's business model is focused on advancing innovation and research in biotechnology and producing high-quality products suitable for both the Polish and international markets. The company is divided into three divisions: medicine, agriculture, and industry, each offering its own products and services. In medicine, Bioton SA offers a wide range of products for prevention, diagnosis, and therapy of various diseases, including diagnostic kits, vaccines, and therapeutics. In the agriculture division, the company aims to improve global food production through the development and production of animal feed and biotechnological enzymes, which enhance the nutrition of livestock and increase the nutritional value of meat, milk, and eggs. In the industry division, Bioton SA develops biotechnological enzymes and processes used in the food and beverage industry, as well as other industries such as textiles and paper, to improve production efficiency and product quality. The company emphasizes its strong presence in research and development, with a team of highly qualified scientists and technicians dedicated to researching and developing new products. Bioton SA also invests heavily in collaboration with universities and research institutes to stay at the forefront of technology and drive continuous innovation. Additionally, the company highlights its strong presence in the international market, with branches in several countries in Europe, Asia, and South America. It also operates several subsidiaries specialized in selling and marketing products in specific markets. Overall, Bioton SA's business model is focused on producing high-quality products while promoting the growth and development of the biotechnology industry. The company emphasizes its presence in various industries and markets and its ability to conduct innovation and research at the highest level.
Il attesa fatturato di Bioton ammonta a 266,00 Mio. PLN. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Bioton ammonta a 12,02 Mio. PLN. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Bioton è attualmente 26,57. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Bioton.
Il rapporto prezzo/fatturato (P/S) di Bioton è attualmente 1,20. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Bioton.
Il Quality Score AlleAktien per Bioton è 3/10.
L'ISIN di Bioton è PLBIOTN00029. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Bioton è A0D9SD. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Bioton è BIO.WA. Con questo simbolo di borsa vengono negoziate le azioni Bioton in borsa.
Azione Bioton
Gruppo di pari di Bioton
Bioton Ticker
Bioton FIGI
Altre metriche e analisi di Bioton in Deep Dive.
La nostra analisi azionaria dell'azione Bioton include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Bioton. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: